The CPH-MBD Cohort
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHerlev Hospital
About this trial
Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population. These increased risks are related to the disturbances in the mineral metabolism, and this clinical entity is termed Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD).
The overall aim of the present project is to explore factors that may predict or associate with the development of bone and cardiovascular disease in patients with CKD and hopefully provide insight into underlying mechanisms and pathophysiological pathways for future treatment and prevention.
In a sub study investigators aim to explore the calcium and phosphate balance in patients with CKD and describe how these associate with each other as well as with kidney function (eGFR).
Eligibility criteria
Qualifiers
Age ≥18 years
CKD stage 4-5nonD (eGFR ≤ 29 ml/min) according to KDIGO (Kidney Disease Improving Global Outcome) definition
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,000 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Herlev Hospital
Lead sponsor
Herlev and Gentofte Hospital
Sponsor institution
Source ClinicalTrials.gov